|
OAPI's
product portfolio is focused primarily in the areas of neuroscience,
oncology, and hospital therapies. In order to meet the needs
of the physicians and other healthcare professionals within these areas, OAPI has hired and trained specialty sales forces for each. If you are
an experienced medical representative with knowledge in these areas, and
are interested in career opportunities with OAPI's oncology,
neuroscience or cardiovascular specialty sales forces,
please visit the
"Careers" section on this Web Site to view positions which are
currently available.
Sales of
ABILIFY®
(aripiprazole) Tablets1 exceeded U.S. $2.6 billion in 2008.
SAMSCATM (tolvaptan)2
has been available for sale
in hospitals since June 2009.
Sales of
IV BUSULFEX®
(busulfan) Injection3 exceeded U.S. $26.9 million in 2008.
Sales of BreathTekTM Urea Breath Test (UBT)4
exceeded U.S. $14.7 million in 2008
Sales of
PLETAL® (cilostazol) Tablets5 increased
the company's revenues significantly since the product was launched.
Annual revenues nearly quadrupled over the period 1999 to 2000 and more
than doubled in 2001. Sales of
PLETAL in 2002, 2003 and 2004 continued a
dramatic growth trend.
|
